Guidance for Ligand Pharmaceuticals Inc. (LGND)
| Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
|---|---|---|---|---|---|---|
| 2026 | $8.00 – $9.00 | $8.42 | $245.00M – 285.00M | $265.70M | = Maintained | Details |
| 2025 | $7.40 – $7.65 | $6.87 | $225.00M – 235.00M | $212.80M | = Maintained | Details |
| 2025 | $6.70 – $7.00 | $6.12 | $200.00M – 225.00M | $194.00M | = Maintained | Details |
| 2025 | $6.00 – $6.25 | $6.11 | $180.00M – 200.00M | $191.30M | = Maintained | Details |
| 2025 | $6.00 – $6.25 | $6.14 | $180.00M – 200.00M | $188.80M | = Maintained | Details |
| 2024 | $5.50 – $5.70 | $5.39 | $160.00M – 165.00M | $156.30M | = Maintained | Details |
| 2024 | $4.25 – $4.75 | $4.44 | $130.00M – 142.00M | $137.30M | = Maintained | Details |
| 2024 | $4.25 – $4.75 | $4.28 | $130.00M – 142.00M | $137.70M | = Maintained | Details |
| 2023 | $5.25 – $5.40 | $5.04 | $126.00M – 129.00M | $126.50M | = Maintained | Details |
| 2023 | $4.85 – $5.00 | $4.63 | $124.00M – 128.00M | $131.00M | = Maintained | Details |
| 2023 | $4.60 – $4.75 | $3.52 | $124.00M – 128.00M | $129.00M | = Maintained | Details |
| 2022 | N/A | N/A | $147.00M – 172.00M | $189.00M | Lowered |
Details |
| 2021 | $5.80 – $6.05 | $5.93 | $265.00M – 275.00M | $270.00M | = Maintained | Details |
| 2021 | $6.15 | $6.17 | $291.00M | $292.00M | = Maintained | Details |
| 2021 | $6.00 | $6.09 | $291.00M | $289.00M | = Maintained | Details |
| 2021 | $6.00 | $5.89 | $285.00M | $277.00M | = Maintained | Details |
| 2020 | $3.95 | $3.91 | $170.00M | $170.20M | = Maintained | Details |
| 2020 | $4.10 | $3.71 | $165.00M | $142.45M | = Maintained | Details |
| 2020 | $3.65 | $3.57 | $140.00M | $129.20M | Raised |
Details |
| 2019 | $6.05 | $6.60 | $224.00M | $243.30M | = Maintained | Details |
| 2018 | N/A | N/A | $240.00M | $234.80M | = Maintained | Details |
| 2018 | $6.30 | $6.21 | $232.00M | $216.58M | = Maintained | Details |
| 2018 | $4.85 | $4.67 | N/A | N/A | = Maintained | Details |
| Q1 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| 2017 | N/A | N/A | $134.00M – 136.00M | $134.50M | = Maintained | Details |
| 2017 | N/A | N/A | $133.00M | $132.40M | = Maintained | Details |
| 2017 | $2.70 | $2.71 | $130.00M | $133.90M | = Maintained | Details |
| 2017 | $2.70 | N/A | N/A | N/A | = Maintained | Details |
| 2016 | $3.41 – $3.46 | $3.37 | $115.00M – 119.00M | $118.50M | = Maintained | Details |
| 2016 | $3.37 – $3.42 | $3.34 | $114.00M – 118.00M | $114.00M | = Maintained | Details |
| 2015 | $2.14 – $2.18 | $2.13 | $81.00M – 83.00M | $82.30M | = Maintained | Details |
| Q2 2015 | $0.37 – $0.40 | $0.35 | $17.00M – 17.50M | $16.40M | = Maintained | Details |
| Q1 2015 | $0.25 – $0.27 | $0.52 | $13.00M – 13.50M | $20.30M | = Maintained | Details |
| 2014 | $1.50 – $1.55 | $1.56 | $64.00M – 66.00M | $64.60M | = Maintained | Details |
| 2014 | $1.50 – $1.55 | $1.44 | $64.00M – 66.00M | $62.90M | Raised |
Details |
| Q4 2014 | $0.57 – $0.62 | $0.67 | $22.50M – 24.50M | $23.50M | = Maintained | Details |
| Q3 2014 | $0.26 – $0.29 | $0.40 | $13.00M – 14.00M | $16.60M | = Maintained | Details |
| Q1 2014 | $0.22 – $0.25 | $0.29 | $13.00M – 14.00M | $15.01M | = Maintained | Details |
| 2013 | $0.49 – $0.51 | $0.50 | $45.00M – 46.00M | $46.03M | = Maintained | Details |
| Q4 2013 | $0.15 – $0.17 | $0.19 | $11.00M – 12.00M | $13.98M | = Maintained | Details |
| 2011 | N/A | N/A | $22.00M – 24.00M | $25.80M | = Maintained | Details |


Lowered
Raised